title: Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy.
abstract: Cumulative inactivation of tumor suppressor genes and/or amplification of oncogenes lead to progressively more malignant astrocytic tumors. We have analyzed the significance of tumor suppressor genes p53, p21, p16 and retinoblastoma protein (pRb) and proliferative activity for survival in 77 high grade astrocytic tumors. After operation, the patients--25 anaplastic astrocytomas (AA) and 52 glioblastomas (GBs)--were treated with similar radiotherapy. The expression of the suppressor genes and the proliferative activity were analyzed immunohistochemically. p53 immunopositivity was found in 44% of AAs and 46% of GBs. Tumors with aberrant p53 expression had lower proliferation indices than p53 immunonegative tumors. Neither p53 expression nor p21 immunonegativity (52% of AAs and 48% of GBs) correlated with survival. p16 immunostaining was negative in 16% of AAs and in 44% of GBs, and it correlated inversely with survival in both uni- and multivariate analyses. pRb immunostaining was negative only in 8% of both AAs and GBs and the absence of p16 and pRb were mutually exclusive. Ki-67 labelling index (LI) was significantly higher in GBs (26.8%) than in AAs (20.3%), and in multivariate analysis it was an independent prognostic factor for survival. In 48% of AAs Ki-67 LI exceeded 20% and this subset of AAs had similar prognosis as GB. In high grade astrocytic tumors p16 immunonegativity was an independent indicator of poor prognosis in addition to the previously established patient's age, histopathology and Ki-67 LI. Furthermore, there was a subset of AAs with a high proliferation rate (> 20%) in which the histopathological hallmarks of GB were lacking, but which had similarly dismal prognosis as GB.
authors.affiliation: Department of Pathology, Turku University Hospital, Finland.
authors.forename: R
authors.initials: R
authors.lastname: Kirla
authors.forename: E
authors.initials: E
authors.lastname: Salminen
authors.forename: S
authors.initials: S
authors.lastname: Huhtala
authors.forename: J
authors.initials: J
authors.lastname: Nuutinen
authors.forename: L
authors.initials: L
authors.lastname: Talve
authors.forename: H
authors.initials: H
authors.lastname: Haapasalo
authors.forename: H
authors.initials: H
authors.lastname: Kalimo
mesh_terms: D000328:Adult; D000368:Aged; D001254:Astrocytoma / Q000235:genetics* / Q000378:metabolism / Q000532:radiotherapy; D001932:Brain Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000532:radiotherapy; D005260:Female; D015870:Gene Expression; D016147:Genes, Tumor Suppressor / Q000502:physiology*; D005909:Glioblastoma / Q000235:genetics* / Q000378:metabolism / Q000532:radiotherapy; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D019394:Ki-67 Antigen